Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: A preliminary investigation

Gynecologic Oncology

Volumn 89, Issue 2, 2003, Pages 233-235

  Wilder, James L ^a   Pavlik, Edward ^a   Straughn, John M ^b   Kirby, Tyler ^b   Higgins, Robert V ^c   DePriest, Paul D ^a   Ueland, Frederick R ^a   Kryscio, Richard J ^d   Whitley, Ronald J ^a   Van Nagell, John ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c CAROLINAS MEDICAL CENTER   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN;

ABDOMINAL CANCER; ADULT; AGED; ANALYSIS OF VARIANCE; AXILLARY LYMPH NODE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL MEDICINE; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC IMAGING; ENDOMETRIOID CARCINOMA; FEMALE; GASTROINTESTINAL DISEASE; HISTOPATHOLOGY; HUMAN; INFLAMMATORY DISEASE; LYMPH NODE METASTASIS; OVARY CARCINOMA; PELVIC INFLAMMATORY DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOGRAPHY; TREATMENT OUTCOME;

EID: 0037404173     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00051-9     Document Type: Conference Paper

References (10)

1. National Institutes of Health Consensus Conference ovarian cancer, screening, treatment and follow-up . JAMA. 8:1995;491-497.
2. Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer statistics. CA Cancer J Clin. 51:2001;15-36.
3. Skates S., Knapp R.C. Early detection of ovarian cancer with tumor markers as first-line test. Curr Prob Obstet Gynecol Fert. 19:1996;84-97.
4. Kabawat S.E., Bast R.C., Bhan A.K., Welch W.R., Knapp R.C., Colvin R.B. Tissue distribution of a coelomic epithelium-related antigen recognized by the monoclonal antibody OC-125. Lab Invest. 48:1983;42.
5. Gadducci A., Zola P., Landoi F., Maggino T., Sartori E., Bergamino T., Cristofani R. Serum half-life of CA-125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer results of a multicentric Italian study . Gynecol Oncol. 58:1995;42-47.
6. Redman C.W., Blackledge G.R., Kelly K., Powell J., Buxton E.J., Luesley D.M. Early serum CA-125 response and outcome in epithelial ovarian cancer. Eur J Cancer. 26:1990;593-596.
7. Gallion H.H., Hunter J.E., van Nagell J.R., Averette H.E., Cain J.M., Copeland L.J., et al. The prognostic implications of low serum CA-125 levels prior to the second-look operations for Stage III and IV epithelial ovarian cancer. Gynecol Oncol. 46:1992;29-32.
8. Skates S.J., Zu F.J., Yu Y.H., Sjovall K., Einhorn N., Chang Y., et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 76:(Suppl.):1995;2004-2010.
9. Skates S.J., Pauler D.K., Jacobs I.J. Screening based on the risk of cancer calculation from Bayesian hierarchical change-point and mixture models of longitudinal markers. J Am Stat Assoc. 96:(454):2001;429-439.
10. Meier W., Baumgartner L., Stieber P., Hasholzner U., Fateh-Moghadam A. CA-125 based diagnosis and therapy in recurrent ovarian cancer. Anticancer Res. 17:1997;3019-3020.